Arkema SA (OTCMKTS:ARKAY – Get Free Report) was the recipient of a large decline in short interest in the month of April. As of April 30th, there was short interest totaling 254 shares, a decline of 77.0% from the April 15th total of 1,104 shares. Approximately 0.0% of the company’s shares are sold short. Based on an average daily volume of 2,415 shares, the days-to-cover ratio is currently 0.1 days.
Arkema Price Performance
ARKAY opened at $73.87 on Friday. The business has a fifty day moving average of $68.40 and a 200 day moving average of $64.73. Arkema has a 52-week low of $56.28 and a 52-week high of $79.36. The company has a quick ratio of 1.63, a current ratio of 2.13 and a debt-to-equity ratio of 0.54. The stock has a market cap of $5.62 billion, a P/E ratio of 295.48 and a beta of 0.84.
Arkema (OTCMKTS:ARKAY – Get Free Report) last posted its quarterly earnings data on Wednesday, May 6th. The basic materials company reported $1.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.91 by $0.10. Arkema had a return on equity of 4.06% and a net margin of 0.46%.The company had revenue of $2.57 billion during the quarter, compared to analysts’ expectations of $2.52 billion. As a group, sell-side analysts anticipate that Arkema will post 3.79 EPS for the current year.
Wall Street Analyst Weigh In
Check Out Our Latest Analysis on Arkema
Arkema Company Profile
Arkema SA is a global specialty chemicals and advanced materials company headquartered in Colombes, France. Established in 2004 as a spin-off from Total’s chemicals division, the company offers a broad portfolio of high-performance materials designed to improve durability, thermal and chemical resistance, and environmental performance across diverse industries.
Arkema’s operations are organized into four core segments. Adhesive Solutions delivers bonding, sealing, and coating technologies for markets such as packaging, medical devices, and consumer goods.
Recommended Stories
- Five stocks we like better than Arkema
- 2 Ways to Play the Big Pharma Patent Cliff
- YETI Rallies After Earnings Beat and Raised Outlook
- How the 3 Leading Quantum Firms Stack Up After Q1 Earnings
- Cisco’s Vertical Rally May Still Be in the Early Innings
Receive News & Ratings for Arkema Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arkema and related companies with MarketBeat.com's FREE daily email newsletter.
